How does rsv start

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 17, 2026

Quick Answer: RSV (Respiratory Syncytial Virus) typically starts when an infected person coughs or sneezes, releasing droplets that others inhale. Symptoms usually appear 4 to 6 days after exposure and include runny nose, cough, and fever, especially in infants and older adults.

Key Facts

RSV was first identified in 1956 from a chimpanzee with a respiratory illness
Over 60% of infants are infected with RSV by age 1, and nearly all by age 2
RSV causes approximately 58,000 hospitalizations in children under 5 annually in the U.S.
The virus is most contagious during the first 3 to 8 days of infection
Seasonal outbreaks typically occur from October to March in temperate climates

Overview

Respiratory Syncytial Virus (RSV) is a common respiratory virus that infects the lungs and breathing passages. While it often causes mild, cold-like symptoms in healthy adults, it can lead to severe illness in infants, older adults, and those with weakened immune systems.

RSV spreads easily through respiratory droplets when infected individuals cough or sneeze. The virus can also survive on hard surfaces for up to 6 hours, increasing the risk of indirect transmission through touch.

First discovered in 1956, RSV was isolated from a chimpanzee with respiratory illness, marking the beginning of virological research into the pathogen.
Transmission occurs primarily through inhalation of infected droplets or contact with contaminated surfaces followed by touching the face, especially eyes or mouth.
Incubation period averages 4 to 6 days, after which symptoms such as runny nose, decreased appetite, and cough begin to appear.
Infants under 6 months are at highest risk for severe complications, including bronchiolitis and pneumonia, due to underdeveloped airways.
Seasonal patterns are consistent, with RSV activity peaking between October and March in the United States, particularly in temperate regions.

How It Works

Understanding how RSV initiates infection involves examining its entry into the body, replication process, and immune response. The virus targets epithelial cells lining the respiratory tract, leading to inflammation and mucus production.

Attachment: RSV uses its G protein to bind to respiratory epithelial cells, initiating the infection process within hours of exposure.
Fusion: The F (fusion) protein allows the virus to merge with the host cell membrane, releasing its genetic material into the cell.
Replication: Once inside, RSV replicates rapidly, producing new viral particles that infect neighboring cells within 24 to 48 hours.
Immune response: The body releases cytokines and recruits white blood cells, causing inflammation and symptoms like fever and cough.
Shedding period: Infected individuals can shed the virus for 3 to 8 days, or up to 4 weeks in immunocompromised patients.
Cell damage: Viral replication leads to the destruction of ciliated cells, impairing mucus clearance and increasing risk of secondary infections.

Comparison at a Glance

RSV shares symptoms with other respiratory viruses, but key differences in transmission, severity, and at-risk populations help distinguish it.

Virus	Incubation Period	At-Risk Groups	Annual U.S. Hospitalizations	Prevention Tools
RSV	4–6 days	Infants, adults over 65	58,000 (children)	Vaccines (older adults), monoclonal antibodies (infants)
Influenza	1–4 days	Children, elderly, pregnant people	140,000–710,000	Vaccines, antivirals
COVID-19	2–14 days	Elderly, immunocompromised	Over 1 million (peak years)	Vaccines, boosters, antivirals
Rhinovirus	1–3 days	All ages	Rare (mild illness)	Hand hygiene, masks
Parainfluenza	2–6 days	Young children	20,000–30,000	No vaccine; supportive care

While RSV causes fewer hospitalizations than influenza or COVID-19, its impact on infants is disproportionately high. Unlike rhinovirus, which causes mild colds, RSV frequently leads to lower respiratory tract infections in babies, requiring medical intervention.

Why It Matters

RSV is a leading cause of pediatric hospitalization and poses significant public health challenges, especially during peak season. Awareness and prevention strategies are critical to reducing transmission and protecting vulnerable populations.

High infant susceptibility: Over 90% of children experience RSV by age 2, with 1–2% requiring hospitalization for breathing difficulties.
Economic burden: RSV costs the U.S. healthcare system over $1 billion annually in direct medical expenses.
Vaccination advances: In 2023, the FDA approved Arexvy and Abrysvo for adults 60+, reducing severe RSV by up to 80%.
Monoclonal antibodies:Nirsevimab, approved in 2022, offers long-lasting protection for infants with one dose.
Global impact: RSV causes over 33 million lower respiratory tract infections annually in children under 5 worldwide.
Long-term effects: Severe RSV in infancy is linked to increased risk of asthma and recurrent wheezing later in life.

With new vaccines and preventive therapies, the outlook for controlling RSV is improving. However, continued public education and access to medical interventions remain essential for reducing its widespread impact.